Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Rovesti

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancers|January 23, 2020
<sup>1</sup>H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma StagesAndrea Casadei-Gardini, Laura Del Coco, Giorgia Marisi, et al.
Frontiers in Immunology|July 5, 2022
Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell ProductsDaniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2025
CAR-T for Lung Cancers: Challenges and InnovationsLucia Trudu, Giulia Rovesti, Giovanni Neri, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|November 16, 2020
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenibAndrea Casadei-Gardini, Giulia Rovesti, Vincenzo Dadduzio, et al.
Journal of Clinical Medicine|April 25, 2020
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population StudyMargherita Rimini, Andrea Casadei-Gardini, Alessandra Ravaioli, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2020
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?Caterina Vivaldi, Francesca Salani, Giulia Rovesti, et al.
American Journal of Cancer Research|October 18, 2021
TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinomaMassimiliano Dall'Ora, Giulia Rovesti, Luca Reggiani Bonetti, et al.
Medicine|June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenibAndrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
Gut|January 20, 2025
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolationPanagiota Maravelia, Haidong Yao, Curtis Cai, et al.
Acta Oncologica (Stockholm, Sweden)|July 20, 2021
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapyRoberto Filippi, Francesco Montagnani, Pasquale Lombardi, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancers|January 23, 2020
<sup>1</sup>H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma StagesAndrea Casadei-Gardini, Laura Del Coco, Giorgia Marisi, et al.
Frontiers in Immunology|July 5, 2022
Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell ProductsDaniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, et al.
Lung Cancer (Amsterdam, Netherlands)|August 16, 2025
CAR-T for Lung Cancers: Challenges and InnovationsLucia Trudu, Giulia Rovesti, Giovanni Neri, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|November 16, 2020
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenibAndrea Casadei-Gardini, Giulia Rovesti, Vincenzo Dadduzio, et al.
Journal of Clinical Medicine|April 25, 2020
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population StudyMargherita Rimini, Andrea Casadei-Gardini, Alessandra Ravaioli, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2020
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?Caterina Vivaldi, Francesca Salani, Giulia Rovesti, et al.
American Journal of Cancer Research|October 18, 2021
TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinomaMassimiliano Dall'Ora, Giulia Rovesti, Luca Reggiani Bonetti, et al.
Medicine|June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenibAndrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
Gut|January 20, 2025
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolationPanagiota Maravelia, Haidong Yao, Curtis Cai, et al.
Acta Oncologica (Stockholm, Sweden)|July 20, 2021
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapyRoberto Filippi, Francesco Montagnani, Pasquale Lombardi, et al.
Pageof 4